19
Sep

At this year’s Bioprocessing Summit, Dr Graham Whyteside presented on 'Inducible synthetic promoters for the production of gene therapy viral vectors'. Synpromics has developed a novel proprietary inducible expression platform that provides exquisite and tuneable control of gene expression.

14
Aug
Synpromics Chemical Stocks

Synpromics announces that it has completed a financing round including £2.1m of new funding from Calculus Capital (“Calculus”). The funds will be used for business expansion and further development of Synpromics’ proprietary synthetic promoter technology.

04
Mar
Characterisation of Synthetic Promoter Activity

Synpromics Limited, a leading synthetic biology company, is pleased to announce that it has formed a collaboration with uniQure N.V., a world leader and pioneer in human gene therapy, to develop synthetic promoters with specific application in the delivery of gene medicines to liver.

20
Aug
Creating Bacterial Synthetic Promoters

Synpromics Limited, a privately held, Scottish-based synthetic biology company today announced that it has successfully generated several highly effective synthetic promoters for use in plants.

27
Mar
Eucaryotic Synthetic Promoter Library Screening

Collaborating with a leading multinational company is an exceptional achievement for this young biotechnology company, based at Edinburgh BioQuarter.

Pages